Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7052W HIGH $4.83
Volume
836.50 K
Value Traded
2.90 M
Short % Float
10.97%
-1.41%Week
-22.5%1 Month
-36.73%3 Month
-31.95%6 Month
-98.21%5 Year
-99.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
276.62 M
EPS (TTM)
-0.91
P/E Ratio
-
Ent. Value
143.65 M
Total Shares
99.14 M
Float Shares
75.05 M
Insiders
24.31%
Institutions
83.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
XFOR Catalyst Timeline
Dated clinical, regulatory and corporate events for X4 Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for X4 Pharmaceuticals, Inc.
158Total events
6Upcoming
55Tier-1 (high impact)
2017 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Debt Royalty FinancingCorporate
X4 enters up to $150M senior secured term loan facility with K2 HealthVentures
▲Type C MeetingMavorixaforApprovedFDA Meeting
Positive outcome from FDA Type C Meeting on revised 4WARD sample size and safety database
chronic neutropeniasource ↗
●R&D DayPresentation
X4 Pharmaceuticals management to participate in fireside chat at 2026 Wells Fargo Healthcare Conference
◆Enrollment UpdateTrial
Continued progress in enrolling global 4WARD Phase 3 Chronic Neutropenia trial
Chronic Neutropeniasource ↗
▲EU ApprovalXOLREMDIApprovedEx-US Regulatory
European Commission approval of XOLREMDI (Mavorixafor) for WHIM syndrome
WHIM Syndromesource ↗
◆Enrollment CompleteMavorixaforApprovedTrial
4WARD Phase 3 trial enrollment completion expected by end of Q3 2026
chronic neutropeniasource ↗
◆Oral PresentationPresentation
X4 Pharmaceuticals to present at 2026 Jefferies Global Healthcare Conference
▲EU ApprovalXOLREMDIApprovedEx-US Regulatory
European Commission granted marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome in the EU
WHIM syndromesource ↗
▲EU ApprovalXOLREMDIApprovedEx-US Regulatory
European Commission grants marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome
WHIM syndromesource ↗
▲CHMP Positive OpinionXOLREMDIApprovedEx-US Regulatory
CHMP positive opinion for mavorixafor in WHIM syndrome
WHIM syndromesource ↗
◆Trial InitiationMavorixaforApprovedTrial
Global pivotal Phase 3 trial (4WARD) evaluating mavorixafor in chronic neutropenia is ongoing
chronic neutropeniasource ↗
◆EU ApprovalMavorixaforApprovedEx-US Regulatory
EC final approval decision anticipated for mavorixafor in WHIM syndrome
WHIM syndromesource ↗
▲CHMP Positive OpinionMavorixaforApprovedEx-US Regulatory
CHMP positive opinion recommending marketing authorization of mavorixafor for WHIM syndrome in EU
WHIM syndromesource ↗
▲CHMP Positive OpinionMavorixaforApprovedEx-US Regulatory
CHMP positive opinion recommending approval of mavorixafor for WHIM syndrome in EU
WHIM syndromesource ↗
◆Oral PresentationPresentation
X4 Pharmaceuticals to participate in Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat
▲CHMP Positive OpinionXOLREMDIApprovedEx-US Regulatory
CHMP positive opinion for XOLREMDI (mavorixafor) for WHIM syndrome
WHIM syndromesource ↗
◆Oral PresentationPresentation
Fireside chat at Guggenheim Second Annual Healthcare Innovation Conference
▼Equity OfferingCorporate
Closing of underwritten public offering of common stock and pre-funded warrants for gross proceeds of $155.3 million
▼Equity OfferingCorporate
Pricing of $135 million underwritten public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
X4 Pharmaceuticals announces proposed underwritten public offering of common stock and pre-funded warrants
▼Restructuring LayoffsCorporate
50% workforce reduction to achieve ~$13M annualized cost savings
◆Management ChangeCorporate
Management changes: Paula Ragan and Adam Mostafa step down; Adam Craig, John Volpone, David Kirske appointed
▲Trial InitiationMavorixaforApprovedTrial
4WARD Phase 3 trial of mavorixafor in chronic neutropenia is underway
chronic neutropeniasource ↗
◆Enrollment CompleteMavorixaforApprovedTrial
Expected full enrollment of Phase 3 4WARD trial
chronic neutropeniasource ↗
▲Poster PresentationMavorixaforApprovedPresentation
Positive Phase 2 chronic neutropenia data presented at EHA 2025
chronic neutropeniasource ↗
◆Timing GuidanceMavorixaforApprovedPresentation
Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia on track for mid-2025
chronic neutropeniasource ↗
▲Enrollment CompleteMavorixaforApprovedTrial
Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia
chronic neutropeniasource ↗
▼Program DiscontinuationCorporate
Discontinuing research efforts and pausing pre-clinical drug candidate programs
▲Partnership / LicenseMavorixaforApprovedCorporate
Licensing and supply agreement with Norgine for commercialization in Europe, Australia, New Zealand
▼Restructuring LayoffsCorporate
Reducing overall headcount by 43 people (approximately 30% of employees)
▲EU MAA SubmissionMavorixaforApprovedEx-US Regulatory
MAA submission for WHIM accepted by EMA
WHIM syndromesource ↗
●EU MAA SubmissionMavorixaforApprovedEx-US Regulatory
EU submission for mavorixafor in WHIM syndrome
WHIM syndromesource ↗
●Runway Guidance UpdateCorporate
Cash runway extended into Q4 2024 excluding potential PRV proceeds
▲Interim AnalysisMavorixaforApprovedTrial
Interim data from ongoing Phase 2 clinical trial of mavorixafor in chronic neutropenia
chronic neutropeniasource ↗
◆Topline ReadoutMavorixaforApprovedClinical Data
Interim Phase 2 data in chronic neutropenia
chronic neutropeniasource ↗
●Debt Royalty FinancingCorporate
Debt draw down of $20 million from loan facility with Hercules Capital
◆PDUFA DateMavorixaforApprovedRegulatory Filing
PDUFA target action date set for mavorixafor
WHIM syndromesource ↗
▲FDA ApprovalXOLREMDIApprovedFDA Decision
FDA approval of XOLREMDI for WHIM syndrome
WHIM syndromesource ↗
Past FDA Catalysts and PDUFA Decisions
How XFOR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-04-29 | Mavorixafor (CXCR4 inhibitor) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$0M
Pipeline Value
$16M
Commercial Value
Richly Valued
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 43%
Micro Cap(rank 284 of 658)
Percentile Rank
X4 Pharmaceuticals, Inc. faces pipeline headwinds (39/100), with 1 assets in development.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $15.8M x 1.0 = $16M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| XOLREMDI | $9M | $5M | +85.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mavorixafor Small moleculeNCT04154488 | Neutropenia | Phase 3 | COMPLETED | 208 | Aug 27, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every XFOR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| mavorixafor BreakthroughPriorityFast Track+1 | chronic neutropenia | Phase 2 | 2025-06-16 | significant increases in neutrophil counts; potential to reduce G-CSF use; clinically meaningful and durable increases in circulating neutrophils; able to reduce injectable G-CSF while maintaining ANC levels in the normal rangeRead More | X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KIRSKE DAVIDOfficer (Chief Financial Officer) | Sell | -11,767 155,983 held | $2.86 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XFOR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 2.2 % (-26.7 %) | 37.21 M | 7.97 M |
XFOR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XFOR ranks across every disease it competes in
Competitive Position is a premium feature
See how XFOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXFOR News
XFOR▼ -1.1%today
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
X4 Pharmaceuticals has secured a senior debt facility of up to $150 million with K2 HealthVentures, enhancing its financial flexibility. The first tranche of $80 million has been used to repay existing loans. The company expects to complete enrollment in its Phase 3 4WARD trial by the end of 2026, with topline data anticipated in the first half of 2028.
Read more →XFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals announced the issuance of inducement awards under its 2019 Inducement Equity Incentive Plan to attract new employees. The awards consist of options to purchase 80,000 shares of common stock, with a ten-year term and an exercise price of $2.90 per share. These options will vest over four years, contingent on continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4).
Read more →XFORX4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
X4 Pharmaceuticals announced its participation in a fireside chat at the 2026 Wells Fargo Healthcare Conference. This event will take place on Thursday, September, and aims to discuss the company's initiatives in rare hematology diseases. The engagement is expected to provide insights into their strategic direction and foster investor relations.
Read more →XFOR▼ -13.2%on this newsshared move
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
X4 Pharmaceuticals announced a positive outcome from its Type C meeting with the FDA regarding the 4WARD Phase 3 trial for mavorixafor. The FDA approved a reduction in the trial's sample size from 176 to 126 participants while maintaining statistical power for key endpoints. Enrollment is expected to complete by the end of 2026, with topline data anticipated in early 2028.
Read more →XFOR▲ +11.3%on this news
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reported its second quarter 2026 financial results, highlighting advancements in its clinical operations aimed at enhancing enrollment in the Global 4WARD Phase 3 trial for chronic neutropenia. The company also celebrated the European Commission's approval of XOLREMDI® (Mavorixafor), marking it as the first authorized treatment for WHIM Syndrome in the EU.
Read more →XFOR▼ -12.5%on this newsshared move
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
X4 Pharmaceuticals has appointed Kelly Gold as the new Chief Financial Officer, effective July 1, 2026. This strategic addition to the Board of Directors aims to strengthen the company's leadership as it focuses on improving the lives of individuals with rare hematology diseases. Gold's extensive experience is expected to benefit the company's future direction.
Read more →XFORX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
X4 Pharmaceuticals will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The presentation will be accessible via a live and archived webcast on their website. X4 focuses on therapies for rare hematology diseases and is advancing mavorixafor, an approved treatment for WHIM syndrome, currently in a Phase 3 trial for chronic neutropenic disorders.
Read more →XFORX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reported its Q1 2026 financial results, highlighting progress in its 4WARD Phase 3 trial for mavorixafor, which is on track for enrollment completion by Q3 2026. The European Commission granted marketing authorization for XOLREMDI, the first treatment for WHIM syndrome in the EU. Despite a net loss of $20.2 million, the company maintains a strong cash position to support its operations through 2028.
Read more →XFORX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
X4 Pharmaceuticals has received European Commission approval for XOLREMDI (mavorixafor), the first treatment for WHIM syndrome in the EU. This authorization follows a positive opinion from the EMA and is aimed at providing a new therapeutic option for patients. The company is also conducting a global Phase 3 trial for chronic neutropenia, further exploring mavorixafor's potential benefits.
Read more →XFOR▲ +18.8%on this news
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reported its financial results for Q4 and full year 2025, highlighting a positive opinion from the European Medicines Agency for mavorixafor's marketing authorization in the EU. The company is on track to complete enrollment in its pivotal 4WARD Phase 3 trial for chronic neutropenia by Q3 2026. Despite a significant operating loss, X4 has a cash runway through 2028, allowing continued development of its therapies.
Read more →XFOR▲ +5.1%on this news· ran to +25% by day 3
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
X4 Pharmaceuticals will participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026. The event will showcase the company's commitment to improving the lives of patients with rare hematology diseases. X4 is currently conducting a pivotal Phase 3 trial for its drug mavorixafor, which has received FDA Fast Track designation.
Read more →XFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026
X4 Pharmaceuticals announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, consisting of options to purchase 24,000 shares of common stock, are intended to attract new talent. The options have a ten-year term and an exercise price equal to the stock's closing price on the grant date. X4 is known for its focus on therapies for rare hematology diseases.
Read more →XFOR▲ +5.8%on this newsshared move
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
X4 Pharmaceuticals has received a positive opinion from the EMA CHMP recommending marketing authorization for mavorixafor to treat WHIM syndrome in the EU. This therapy, which addresses a significant unmet medical need, is expected to be the first of its kind in Europe. The final decision from the European Commission is anticipated in the second quarter of 2026.
Read more →XFORX4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
X4 Pharmaceuticals will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026. The management team will hold a fireside chat and is available for one-on-one meetings with investors. The event highlights X4's commitment to advancing therapies for rare hematology diseases, including their marketed product, mavorixafor.
Read more →XFORX4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
X4 Pharmaceuticals will participate in the Guggenheim Second Annual Healthcare Innovation Conference from November 10-12, 2025. The management team will hold a fireside chat on November 10th at 8:30 a.m. ET and will be available for one-on-one investor meetings. A webcast of the chat will be accessible on the company's website.
Read more →XFOR▼ -10.6%on this newsshared move
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reported its Q3 2025 financial results, highlighting a renewed focus on the 4WARD Phase 3 trial for mavorixafor in chronic neutropenia. The company achieved $240.3 million in financing, extending its cash runway to 2028. However, it also reported a net loss of $29.8 million for the quarter, indicating ongoing financial challenges.
Read more →About X4 Pharmaceuticals, Inc.
Headquarters61 NORTH BEACON STREET, BOSTON, MA, 02134
BIOPHARMAWATCH ELITE PLUS
Trade the next XFOR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime